Author: Editor

Paul G. Richardson, MD, explains Combinations with RVD Beyond Daratumumab Data with ixazomib, revlimid, & dexamethasone at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains RVD-Lite Mission Treating Over 50 Patients Regimen of Bortezomib, lenalidomide, steroids at Imedex Great Debates 2018.

Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB).

Dr. Rachel Sanborn, Providence Thoracic Oncology Program, discusses the topic of lung cancer and that there is an entire spectrum of different kinds of cancers that have started inside the lungs. Small cell lung cancers behave very differently than non-small cell lung cancer.

On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to share the videos from this live and webcast forum. Our first video welcomes all to the event, and it was our extreme pleasure to have Chris Draft and Dr. Ross Camidge join us to start the day! This is followed by Does NED matter? Using curative surgery or radiation techniques to treat “incurable” advanced lung cancer, with Dr. Rob Meguid, and a panel discussion featuring Dr. Meguid, Dr. Chad Rusthoven,…

Paul G. Richardson, MD, explains Selinexor is a Novel Mechanism of Action Venetoclax Serves a Challenging Population at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Role of Venetoclax in Plasma Cell Leukemia Excellent partner drug with non-overlapping toxicities at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Powerful new IMiDs, CC-220 & CC-92480 Importance of Small Molecules in advanced trials at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Melflufen is a Modified Derivative of Melphalan Peptidase-avid and a targeted form of chemotherapy at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Selinexor is an Inhibitor of Nuclear Export Proteins Synergy with Bortezeomib on anti-myeloma activity at Imedex Great Debates 2018.

Paul G. Richardson, MD, explains Venetoclax Shown Great Results with Bortezomib It targets 11;14, oral, well-tolerated at Imedex Great Debates 2018.

On August 20, 2016, in collaboration with the University of Colorado Cancer Center, GRACE presented the Targeted Therapies in Lung Cancer Patient Forum in Aurora Colorado. We are happy to share the videos from this live and webcast forum. Our second video is the first part of the forum breakout session for ALK + patients and caregivers, featuring Dr. Shirish Gadgeel and patient moderator Linnea Olson.

GRACE is happy to present the 9th and final video in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

Jose F. Leis, MD, PhD, explains how Control of disease can be achieved with Ibrutnib High-risk Relapsed Refractory patients will progress at Imedex Great Debates 2018.

Richard R. Furman, MD, talks about how MBL Patients Don’t Need Bone Marrow Biopsies MBL can be followed by CBCs and Physical Exams at Imedex Great Debates 2018.

Amer M Zeidan, MBBS, explains 4 New Drugs in the Treatment Landscape for AML Incorporating the new drugs in to AML management at Imedex Great Debates 2018.

Jose F. Leis, MD, PhD, explains Venetoclax Rapidly Moving as Best 2nd-line Therapy SCT still remains as the only curative treatment Imedex Great Debates 2018.

Matthew S. Davids, MD, MMSc, talks about how Venetoclax w Rituximab progressed the furthest Phase 3 Data shows the combination is superior Imedex Great Debates 2018.

Richard R. Furman, MD, talks about how MBL Patients Don’t Need Bone Marrow Biopsies MBL can be followed by CBCs and Physical Exams at Imedex Great Debates 2018.

Jose F. Leis, MD, PhD, explains PET-Scans Not as Specific for Richter’s Transformation Biopsies are essential for those who fail new therapies at Imedex Great Debates 2018.

Amer M Zeidan, MBBS, talks about A lot of Questions on the Best Use of New Drugs Still waiting on more data, stick to the label at Imedex Great Debates 2018.

Matthew S. Davids, MD, MMSc, explains Role of Chimeric Antigen Receptor T Cells CAR-T Cell after multiple novel agent-based therapies at Imedex Great Debates 2018.

Richard R. Furman, MD, explains how Prognostics are difficult in the MBL population Del17P & NOTCH1 are relevant for time to treatment at Imedex Great Debates 2018.

Amer M Zeidan, MBBS, explains Enasidenib, an IDH2 Inhibitor based on Phase 1 Trial High-Response rate in patients with IDH2 mutation at Imedex Great Debates 2018

Jose F. Leis, MD, PhD, explains the Treatment of CLL & Richter’s Transformations High Risk Patients will progress their disease at Imedex Great Debates 2018.

Richard M. Stone, MD, talks about Incorporating Midostaurin for FLT3 Positive Patients Use Gemtuzumab Ozogamicin for CD33 Expression at Imedex Great Debates 2018.

GRACE is happy to present the 7th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016.

GRACE is happy to present the 6th video in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss whether current evidence supports favoring proton beam radiation.

http://cancerGRACE.org/

GRACE is happy to present the 5th in our series ASCO 2016 Lung Cancer Roundtable, Highlights and New Approaches in Lung Cancer. Featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD, this roundtable discussion, moderated by Dr. West, highlights the newest and most intriguing discussions from ASCO 2016. Drs. West, Vokes and Ramalingam, along with patient advocate Janet Freeman-Daily, discuss the J-Alex trial and whether Alecensa should replace Xalkori as First-Line ALK Therapy.

3rd video in GRACE ASCO 2016 Lung Cancer Roundtable series, featuring Jack West, MD, Janet Freeman-Daily, Everett Vokes, MD, and Suresh Ramalingam, MD. Dr. West moderates the subject of urine or blood test vs lung biopsy, and finding EGFR mutations.

In this sixth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the breakout session for EGFR patients and caregivers, featuring Drs.Greg Riely Jack West, and patient moderator Bob Fuerst.

In this eighth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the lunchtime keynote discussion: The Evolving Landscape of Molecular Testing in Lung Cancer: Who, How and When? featuring Dr. Dara Eisner.

In this seventh video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the lunchtime Lung Cancer Champion Award presented to Chris Draft by GRACE founder, H. Jack West.

Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joined GRACE to discuss the basics of lung cancer for Spanish speaking patients and caregivers. In this video, Dr. Santana-Davila joined GRACE to discuss the general approach to limited stage small cell lung cancer.

Dr. Rafael Santana-Davila, Assistant Professor of Medicine at the University of Washington, Seattle Cancer Care Alliance joined GRACE to share information on the general approach to extensive stage small cell lung cancer for Spanish speaking patients and caregivers.

In this ninth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The first video from these sessions is Bankruptcy and Workplace Discrimination, presented by Patricia McMahon and Carlos Colon, AFC.

In this tenth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The second video from these sessions is The Cancer Kitchen, with Lisa Wingrove, RD, CSO. Lisa is joined in this video by her lovely kitchen helper, Chris Draft.

In this twelfth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The fourth video from these sessions is Dealing with Down Days, presented by Jeanice Hansen, MSW, LCSW, OSW-C.

During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. In this fifth video we feature our friend Rita Johnson

During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. In this first video we feature our friend Linnea Olson.

During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. In this third video we feature our friend Don Fredal

During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. In this sixth video we feature our friend Ann Broo.

In this thirteenth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The fifth video from these sessions is Exercise for Lung Cancer Patients, presented by Jeffrey Eagan DPT.

In this eleventh video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The third video from these sessions is Chemo Brain, with Denise Damek, MD.

In this fourteenth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The sixth video from these sessions is Love, Sex and Cancer, presented by Dr. Helen Coons.

In this sixteenth and final video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The eighth video from these sessions is Recharging the Caregivers Batteries, with Jeanice Hansen, MSW, LCSW, OSW-C.

Dramatic progress has been made in our understanding of the clinical, biological and molecular heterogeneity of chronic lymphocytic leukemia (CLL). Despite this, treatment challenges remain, particularly in patients with high-risk disease. This Velocity Vlog activity featuring Dr. John N. Allan addresses the question of how to integrate the latest knowledge into clinical practice to help guide treatment choices for patients with high-risk CLL. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=CLL © 2018 Imedex, LLC.

On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung Cancer Initiative of North Carolina, to discuss with top providers the newest information on Squamous Cell Lung Cancer. This webcast was made available live online, and we are excited to present the videos, now available for viewing. Our first presentation discusses what is squamous lung cancer, with Chad Pecot, MD.

On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung Cancer Initiative of North Carolina, to discuss with top providers the newest information on Squamous Cell Lung Cancer. This webcast was made available live online, and we are excited to present the videos, now available for viewing. Our second presentation discusses currently available treatment options, with Jared Weiss, MD.

On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung Cancer Initiative of North Carolina, to discuss with top providers the newest information on Squamous Cell Lung Cancer. This webcast was made available live online, and we are excited to present the videos, now available for viewing. Our third presentation discusses future directions in treatment, with Chad Pecot, MD.

Hyperhydration is typically used along with high-dose melphalan in patients undergoing stem cell transplantation. However, the evidence behind this practice is limited and the dosage administered to patients needs refining. In this interview, Midori Nakagaki, BPharm, MSc, from the Royal Brisbane Hospital, Brisbane, Australia, discusses the findings of her groups study retrospectively comparing patients response with hyperhydration vs. without hyperhydration. Midori emphasizes the advantages in reducing dosage, namely easing the workload for healthcare professionals and minimizing the pressures on patients. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting in Lisbon, Portugal.

The European Society for Blood and Marrow Transplantation (EBMT) have recently set up their dedicated EBMT Patient Advisory and Advocacy Committee, to encourage and support patient and advocate involvement in stem cell transplantation. Here, Anita Waldmann from the Leukaemia Patient-Support Group RHEIN-MAIN, Rüsselsheim am Main, Germany, talks about the Committees recent success and future aims. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting in Lisbon, Portugal.

Blood and bone marrow transplantation continues to experience breakthroughs, with the role of the patient becoming increasingly important. In this talk, Anita Waldmann from the Leukaemia Patient-Support Group RHEIN-MAIN, Rüsselsheim am Main, Germany, discusses the needs of blood and marrow transplant patients, and why transplant centers should focus on these needs. Speaking from the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting in Lisbon, Portugal, Anita stresses the power of the patients voice in influencing policy.

The Worldwide Network for Blood & Marrow Transplantation (WBMT) is an umbrella organization for institutions and centers carrying out blood and marrow transplants. Here, Anita Waldmann from the Leukaemia Patient-Support Group RHEIN-MAIN, Rüsselsheim am Main, Germany, discusses the role of the WBMT in supporting countries to set up blood and marrow transplant institutions. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting in Lisbon, Portugal.

Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia, and can present de novo or following the early symptoms of plasma cell myeloma. Patients with PCL tend to present with aggressive clinical features, such as extramedullary disease. Here, Torben Plesner, MD, from the University of Southern Denmark, Vejle, Denmark, discusses the challenges in treating patients with these aggressive subtypes of multiple myeloma, as optimal therapies havent been designed for this patient population. This video was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.

The incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma (MM). In this video, Torben Plesner, MD, from the University of Southern Denmark, Vejle, Denmark, discusses the variety of agents used in the therapeutic management of MM. This interview was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.

Systemic amyloid light-chain (AL) amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly, but treatment and outcomes have not been systematically studied in this group of patients. Here, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, discusses the clinical profile and treatment outcomes of this patient population, from an analysis conducted by his group. Dr Merlini highlights the most effective treatment approach indicated by this data. This video was recorded at the 2018 European Myeloma Network (EMN) Meeting, in Turin, Italy.

New insights into the biology of multiple myeloma (MM) are continually emerging. In this interview, Martin Kaiser, MD, of the Institute of Cancer Research, London, UK, covers what is known about Monoclonal Gammopathy of Undetermined Significance (MGUS) and clonal succession in MM. Dr Kaiser then considers whether this could be targeted, particularly in terms of predicting disease progression. This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.

A large contributing factor to outcome in amyloidosis is the stage of diagnosis. Here, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, discusses the need to improve outcomes in patients with very advanced (stage IIIb) cardiac amyloid light-chain (AL) amyloidosis. Dr Merlini emphasises the importance of early diagnosis for this patient population using biomarkers and imaging, to supress the light-chains amyloid deposits early on, and change the outlook of these patients. This video was recorded at the 1st European Myeloma Network Meeting, in Turin, Italy.

This is an exciting time for the treatment of amyloid light-chain (AL) amyloidosis, with a number of novel therapies on the horizon. In this interview, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, discusses the novel agents currently in clinical trials, which can target the amyloid deposits characterizing the disease. Dr Merlini highlights NEOD001 (Phase III VITAL study; NCT02312206) and the combination of CPHPC and anti-serum amyloid P component antibodies (NCT01777243). This video was recorded at the 1st European Myeloma Network Meeting (EMN), in Turin, Italy.

New insights into amyloid light-chain (AL) amyloidosis have emerged in recent years. Here, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, gives an overview of the mechanisms behind this rare condition at the 1st European Myeloma Network Meeting (EMN), in Turin, Italy. Dr Merlini then discusses the importance of biomarkers in the reflection of pathogenic mechanisms of AL amyloidosis, highlighting key biomarkers, such as NT-proBNP and GDF-15.

There are now many options to treated relapsed/refractory multiple myeloma (MM); however, these drugs can be costly, and access differs between countries and locations. In this interview, Jean-Luc Harousseau, MD, of the University of Nantes, Nantes, France, discusses the recommendations for and challenges of treating at relapse from a cost/efficacy point of view. Dr Harousseau discusses how this can assessed and understood, as well as how treatment duration is considered and how clinical trials can be designed to optimize this measure. This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.

As our knowledge of the genetics of multiple myeloma (MM) advances, we can more precisely understand and target the disease. Here, Martin Kaiser, MD, of the Institute of Cancer Research, London, UK, discusses how different classes of genetic abnormalities in MM could be targeted. Dr Kaiser highlights exciting work on the t(4;14) translocation in MM and tissue agnostic therapies.This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.

There are an array of new strategies evolving to manage relapsed chronic lymphocytic leukemia (CLL). In this interview, George Follows, MA, BM, BCh, PhD, FRCP, FRCPath, from Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the exciting UK CLL Forum analysis of patients treated with ibrutinib at first relapse. Dr Follows highlights the fascinating results identified between patients with early and late relapse. This interview was recorded at the British society for Hematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK.

The treatment of relapsed/refractory lymphoma can prove to be challenging. PEP-C (prednisone, etoposide, procarbazine, and cyclophosphamide) is an oral combination therapy regimen used for such patients. Here, George Follows, MA, BM, BCh, PhD, FRCP, FRCPath, from Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses the Cambridge University Hospitals and Anglia regional experience of the benefits of using PEP-C over the past 8 years. This interview was recorded at the British society for Hematology (BSH) 2018 Annual Scientific Meeting, in Liverpool, UK.

An exciting array of data for myeloproliferative neoplasms (MPNs) was presented at the 2018 British Society for Hematology (BSH) Annual Scientific Meeting, held in Liverpool, UK. Speaking from the meeting, Claire Harrison, MD, FRCP, FRCPath, from Guys and St Thomas Hospital NHS Foundation Trust, London, UK, talks about the exciting clinical trials currently being conducted in MPNs. Prof. Harrison discusses a study aiming to improve the management of very young MPN patients, which may be used as a pilot to set up a collaboration across Europe, to rapidly generate data that can be used in further understanding this patient population…

An upcoming study is investigating a new therapeutic strategy for the treatment of myeloproliferative neoplasms (MPNs). In this interview, Claire Harrison, MD, FRCP, FRCPath, from Guys and St Thomas Hospital NHS Foundation Trust, London, UK, gives an overview of the TAMARIN study (ISRCTN65011803); a study supported by Bloodwises Trials Acceleration Programme (TAP), investigating the effects of the anti-estrogen therapy tamoxifen on JAK/CALR mutant allele burden and disease course in patients with MPNs. Prof. Harrison highlights the rationale and design of this upcoming study. This video was recorded at the 2018 British Society for Hematology (BSH) Annual Scientific Meeting in Liverpool,…

This is an exciting time for chronic myeloid leukemia (CML) and myeloproliferative neoplasms (MPNs), with new treatments on the horizon. Here, Claire Harrison, MD, FRCP, FRCPath, from Guy’s and St Thomas’ NHS Foundation Trust, London, UK, gives an overview of the session she chaired on individualizing care for patients with CML and MPNs at the 2018 British Society for Hematology (BSH) Annual Scientific Meeting in Liverpool, UK. Prof. Harrison touches upon the program, which was designed with an overlap for the two conditions in mind, addressing several of the session speakers, including Adam Mead, who spoke on stem cell dynamics…

Consent for transplant, from both the patient and healthcare professionals, is critical. In this interview, Angela Leather from the Christie NHS Foundation Trust, Manchester, UK, recollects a case that places emphasis on consent and full disclosure in patient transplants. Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Angela emphasizes that incidences such as this provide opportunities to learn and refine protocols.

Post-transplant complications are an important issue to consider and must be managed appropriately. Here, Angela Leather from the Christie NHS Foundation Trust, Manchester, UK, talks about the problems with unseen graft versus host disease (GvHD) and sexual health in women. She highlights the importance of identifying post-transplant complications in women early, particularly in the case of GvHD, and encourages both patients and healthcare professionals to be open about talking about this. This video was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

CAR T-cell agents, as a breakthrough therapy, have their challenges. Here, Rose Ellard from Kings College Hospital NHS Foundation Trust, London, UK, outlines the importance of formal training in managing the side effects of CAR T-cell therapy. She also highlights the need for networking between healthcare professionals on the frontline in an area that is still being learned about. This video was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

CAR T-cell therapy is a new and exciting advancement for the treatment of hematological cancers. In this interview, Rose Ellard from Kings College Hospital NHS Foundation Trust, London, UK, talks about the breakthrough clinical trials for CAR T-cell agents currently being held in the UK, and the management of potential side effects. Cytokine release syndrome, for example, requires prompt recognition of the symptoms and management with specialist care. This video was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.

Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and negative (<1%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset.

Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and low (1-49%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset.

Amer M Zeidan, MBBS, Gemtuzumab ozogamicin, Antibody Drug Conjugate Broad approval covering front-line & relapse settings at Imedex Great Debates 2018

Matthew S. Davids, MD, MMSc, Data Combining Venetoclax with Rituximab Half of patients achieved complete remission at Imedex Great Debates 2018.

Richard R. Furman, MD, explains 17P Deleted with TP53 need to be treated differently at Imedex Great Debates 2018.

Jose F. Leis, MD, PhD, explains Chimeric Receptor Therapies for CLL Complete remission rates range from 25-50 at Imedex Great Debates 2018

Richard M. Stone, MD, explains Use a PCR-based Approach for NMP1 Gene Next-gen sequencing to measure MRD at Imedex Great Debates 2018.

Amer M Zeidan, MBBS, CPX-351, a lysosomal formulation of 7+3 Drug has been tested with significant survival at Imedex Great Debates 2018.

Amer M Zeidan, MBBS, explains Midostaurin – FLT3 Inhibitor Improved survival when drug is added to standard at Imedex Great Debates 2018.

Matthew S. Davids, MD, MMSc, discusses Durability of Response for Agents is Short for Del17P Develop novel combination therapies

Richard R. Furman, MD, PFS has to be Emphasized for CLL Treatments Chemotherapy is unnecessary with novel combinations at Imedex Great Debates 2018

Jose F. Leis, MD, PhD, discusses the Sequencing of Therapeutic Interventions Venetoclax outperforms chemoimmunotherapy at Imedex Great Debates 2018.

Richard M. Stone, MD, discusses 4 New Drugs in the Treatment Landscape for AML Incorporating the new drugs in to AML management at Imedex Great Debates 2018

Amer M Zeidan, MBBS, discusses Novel Treatments for Acute Myeloid Leukemia Four New Drugs Approved at Imedex Great Debates 2018.

Alison Fielding, MD, presents A Patient View at the International Kidney Cancer Symposium 2018

Lisa M Pickering, MD, presents Centralisation of RCC Management: What is the volume needed to improve? The Oncologists View: Is there an argument for centralisation? at the International Kidney Cancer Symposium 2018

Mr. Rajesh Nair FRCS (Urol.), FEBU, MSc., presents Centralisation of Renal Cell Carcinoma Management: What is the Volume Needed to Improve? The Surgeons Point of View at the International Kidney Cancer Symposium 2018

Guillermo de Velasco MD, PhD, presents Treatment after Immune checkpoint inhibition: Impact on biology? at the International Kidney Cancer Symposium 2018.

Laurence Albiges, MD, PhD, presents Treatment after immune checkpoint in first/second line setting: Clinical perspective at the International Kidney Cancer Symposium 2018

Ravi Barod PhD FRCS (Urol) presents Minimally invasive partial nephrectomy is NOT a cause of seeding of RCC at the International Kidney Cancer Symposium.

Christopher G. Wood, M.D., F.A.C.S. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX chairs an esteem panel to discuss challenging renal cases at the International Kidney Cancer symposium 2018. Viktor Grunwald, Camillo Porta, Seva Matveev, Karim Bensalah

Paul Russo, MD, FACS, presents DEBATE: Cancer Seeding and Minimally Invasive Kidney Tumor Surgery at the International Kidney Cancer Symposium 2018

Co-chair Dr. John P. Leonard summarizing the key take-home points presented during the Lymphoma session at this years Great Debates & Updates in Hematologic Malignancies conference. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Hema © 2018 Imedex, LLC.

Co-chair Dr. David P. Steensma summarizes the key take-home points presented during the sessions on leukemia, benign hematology, and myeloid disorders at this years Great Debates & Updates in Hematologic Malignancies conference. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Hema © 2018 Imedex, LLC.

Guest faculty Dr. Paul G. Richardson summarizes the key take-home points from the presentations comprising this years Plasma Cell Disorders session at the 2018 Great Debates & Updates in Hematologic Malignancies conference. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Hema © 2018 Imedex, LLC.

Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and high tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of these patients.

Sumanta Kumar Pal, M.D. Associate Professor, Department of Medical Oncology & Therapeutics Research Co-Director, Kidney Cancer Program City of Hope Comprehensive Cancer Center discusses the New Generation of Biomarkers for IO: Fact or Fiction? at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Bernard Escudier, Gustave Roussy, Villejuif, France asks teh question “Combination Trials with New IO Agents: How Can we Define the Best Treatment with Current Data?” at the 13th European International Kidney Cancer Symposium 2018 in Prague.

On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung Cancer Initiative of North Carolina, to discuss with top providers the newest information on Squamous Cell Lung Cancer. This webcast was made available live online, and we are excited to present the videos, now available for viewing.

Presented by Dr. Luis E. Raez, MD, FACP, FCCP Chief of Hematology/Oncology and Medical Director of Memorial Cancer Institute (Miami, FL) Clinical Associate Professor of Medicine, Herbert Wertheim College of Medicine, Florida International University

Brian I. Rini, MD, Cleveland Clinic discusses VEGF + I/O combinations in Renal Cell Carcinoma at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Hans Hammers, MD, PhD, Associate Professor, UT Southwestern takes the pro stance during a debate on IO/IO in 1st Line at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Samra Turajlic, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust CRUK Clinician Scientist, The Francis Crick Institute discusses Tracking the evolution of renal cell carcinoma: TRACERx Renal at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Dr. Lisa Derosa, MD, PhD Candidate Immunoncology – Pr. L. Zitvogel discusses The Role of the Microbiome in Immunotherapy at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Samra Turajlic, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust CRUK Clinician Scientist, The Francis Crick Institute discusses the neo-antigen landscape in renal cell carcinoma at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Dr James Larkin, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust discusses “Immunotherapy: Bridging Knowledge from Melanoma” from a Kidney Cancer point of view at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Alain Ravaud MD, PhD, of Centre Hospitalier Universitaire de Bordeaux, Bordeaux CHU Bordeaux accepts the P.H.M. DeMulder Memorial Lecture with a presentation entitled “Have we done a good enough job in influencing our regional or national oncology communities regarding RCC care? Probably not.” at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Tim Eisen, University of Cambridge discusses Patient Expectations of Adjuvant Therapy in Kidney Cancer at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Lauren Harshman MD, Co-director of Kidney Cancer Program Dana-Farber Cancer Institute/Harvard Medical School discusses Biologic Rational For Neoadjuvant OVER Adjuvant Approach with IO at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Axel Bex, The Netherlands Cancer Institute Amsterdam debates the side of No Adjuvant Therapy Kidney Cancer at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Michael Staehler, Ludwig-Maximilians-University of Munich | LMU discusses Yes for Adjuvant Therapy with Full Dose VEGFR TKI at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Maxine Tran, Senior lecturer and Honorary Consultant Urologist Specialist center for kidney cancer, Royal Free Hospital UCL Division of Surgery and Interventional Science asks the question “Can renal tumour biopsies prevent unnecessary interventions?” at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Tom Mitchell BMBCh, DPhil, FRCS, Academic Clinical Lecturer & Honorary Urology Registrar, Cambridge University Hospitals discusses Timing of Key Genetic Events In Renal Cancer and Possible Prevention Strategies at the 13th European International Kidney Cancer Symposium 2018 in Prague.

Grant D Stewart, University Lecturer, University of Cambridge, Consultant Urological Surgeon, Addenbrookes Hospital asks the question “Screening for kidney cancer: why not?” at the 13th European International Kidney Cancer Symposium 2018 in Prague.

The British Society for Haematology (BSH) aims to improve patient care and outcomes in the hematology field. In this interview, 2017/18 BSH President Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses how the BSH is accelerating improvements in hematology. Prof. Craddock highlights interactions with clinical trials groups, as well as the importance of genomics and big data. This video was recorded at the 2018 BSH Annual Scientific Meeting in Liverpool, UK.

The British Society for Haematology (BSH) brings hematology professionals from all areas together at their Annual Scientifc Meeting. Speaking from the 2018 meeting, 2017/18 BSH President Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, passionately talks about the highlights and take-home messages from the meeting.

IMPACT, the UKs first large-scale clinical trials platform for patients receiving a stem cell transplant, is launching in 2018. Here, Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses plans for the first year of IMPACT, with four prospective randomized trials set to be launched. Prof. Craddock covers the trials and rationale behind them, including COSI and PRO-DLI, which is the first randomized study investigating the benefit of donor lymphocytic infusions for the prevention of relapse post-HSCT in patients with high-risk myeloid malignancy. This video was recorded at the 2018 British Society for Hematology…

Recent KEYNOTE study data has led to confusion over the significance of PD-L1 as a predictive biomarker of immunotherapy response. The lack of a standardized assay for PD-L1 also makes things trickier. In this interview, Fred Hirsch, MD, PhD, CEO of the International Association for the Study of Lung Cancer (IASLC), from the University of Colorado, Denver, CO, discusses the standardization of PD-L1 assays. Dr Hirsch gives an update on the results of the Blueprint PD-L1 IHC Assay Comparison Project, which is investigating how comparable the results of the five main PD-L1 assays are. This video was recorded at the…

The results of KEYNOTE-024 (NCT02142738) indicated that high PD-L1 expression predicted a benefit from pembrolizumab vs. chemotherapy. However, new data suggests that the picture is less clear than this. This new data and what messages can be taken from it are explained here by Fred Hirsch, MD, PhD, CEO of the International Association for the Study of Lung Cancer (IASLC), from the University of Colorado, Denver, CO. Dr Hirsch highlights results observed in low PD-L1 expression conditions from KEYNOTE-042 (NCT02220894), which investigated pembrolizumab monotherapy vs. chemo, as well as data from KEYNOTE-189 (NCT02578680) where PD-L1 expression was not used for…

Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizumab or placebo added to cisplatin or carboplatin with pemetrexed chemo in advanced non-squamous NSCLC with any PD-L1 expression.

A Practice Change for ALK+ Lung Cancer Patients, Alecensa for First Line Treatment

Sequencing Treatments for ALK+ Lung Cancer in a Crowded Field Is there a place for Lorlatinib?

Are MET Mutations Now a Mutation We Should Look for in Lung Cancer?

Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC: New Option or Too Little Too Late?

Keytruda is Now Approved in Combination with Chemo for Advanced Non-Squamous NSCLC: What Do We Do Now?

What is PFS2 in Advanced NSCLC, and Should we Care? Unique Analysis of the KEYNOTE-024 trial         KEYNOTE-024 trial, Advanced NSCLC, PFS2

What is the role for Immunotherapy in Relapsed Small Cell Lung Cancer after ASCO 2017?

Emerging Options for Malignant Pleural Mesothelioma

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Radiation oncologist Dr. Chris Loiselle reviews the possibility of re-treating with radiation for lung cancer, typically using stereotactic technique, in a previously irradiated field.

Why radiate a perfectly good brain? Dr. Vivek Mehta, radiation oncologist, discusses the possible role for prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (SCLC) to decrease risk of brain metastases and improve survival.

Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.

MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.

Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.

Drs. Leora Horn, Ben Solomon, & Jack West debate whether results from a European trial of chest radiation after chemotherapy for extensive stage small cell lung cancer should lead to a change in treatment for this setting.

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib

Dr. Nasser Hanna, Indiana University Health, describes the factors which determine whether stage III NSCLC is resectable.

Join us for the 2017 Targeted Therapies in Lung Cancer Patient Forum, Saturday, September 16, 2017, at the Taussig Cancer Center, Cleveland Clinic. For more info and registration, visit http://cancergrace.org/lung/targeted-…

Afternoon Session – Targeted Therapies in Lung Cancer Patient Forum Breakout Webcast Recording – MET/RET/BRAF, with Dr. Karen Reckamp, Dr. Vamsidhar Velcheti, and Sara Whitlock, RET patient.

Dr. Jame Abraham, Director of the Breast Oncology program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Lerner College of Medicine, as he shares his experience and insight into the importance of clinical trials, their accrual rates and the phase I and phase II trials with Neratinib. @NSABPFoundation @jamecancerdoc

In this weeks video, Dr. Brian G.M. Durie explains which criteria and tests determine if a patients myeloma is smoldering or active. BOTTOM LINE: Only treat myeloma if test results are absolutely clear and show active disease.

Radical thoracic radiotherapy is a mainstay in the treatment of non-small cell lung cancer (NSCLC); however, the effect of cardiac doses on survival is becoming increasingly important, as highlighted by the RTOG 0617 study (NCT00533949). Here, Matthew Hatton, MBChB, MRCP, FRCP, FRCR, of the Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, discusses his groups exciting work investigating the effect of different cardiac doses of radiotherapy on patient outcomes. Dr Hatton highlights the significance of this work, being different compared with reported study outcomes, due to the use of accelerated and sequential radiotherapy regimens in the real-world setting. He then…

In this weeks video, Dr. Brian G.M. Durie explains that maintenance therapy can prolong remissions and delay relapse. The BOTTOM LINE: If maintenance therapy is well-tolerated, stick with it!

In this weeks video, Dr. Brian G.M. Durie explains that if you relapse on Darzalex, it is important to carefully discuss all treatment options with your doctor. BOTTOM LINE: If you relapse while on Darzalex, consider all options including upping dosing, new combination therapies, second transplant, or even a clinical trial.

In this weeks video, Dr. Brian G.M. Durie explains why genetic sequencing tests are not yet precise enough to use for choosing myeloma therapies. BOTTOM LINE: We may be able to specify myeloma treatments based on genetic subtypes in the future, but not quite yet!

The anti-PD-1 antibody therapy pembrolizumab is an exciting new agent for the treatment of non-small cell lung cancer (NSCLC). Here, Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, discusses the use of pembrolizumab monotherapy in the first-line setting, referencing KEYNOTE-024 data (NCT02142738). Prof. Reck then goes on to discuss the next steps for investigating pembrolizumab combination therapy, such as that being explored in the Phase III KEYNOTE-189 trial (NCT02578680). This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

The IMpower150 trial (NCT02366143) was the first to explore chemotherapy, immunotherapy with atezolizumab and anti-angiogenic therapy with bevacizumab for non-small cell lung cancer (NSCLC). In this interview, Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, discusses the aims and design of the study, in addition to an exciting data update pre-ASCO. Prof. Heck highlights the broad spectrum of this study, meaning that patients with different types of mutations, including EGFR and ALK, were eligible. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

Immunotherapeutic agents are increasingly becoming incorporated into clinical practice; however, there is still much to learn, including their optimal combinations, sequencing and usage. In this interview, Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, discusses whether we can improve the efficacy of immunotherapy in lung cancer patients who have not been selected for their high PD-L1 expression. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

The Phase III KEYNOTE-024 trial (NCT02142738) compared pembrolizumab monotherapy with standard platinum-based chemotherapy for previously untreated metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. Speaking from the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Martin Reck, MD, PhD, of the Lung Clinic Grosshansdorf, Grosshansdorf, Germany, gives an overview of the trial and an update on the progression-free survival results observed in the trial.

The European Lung Cancer Congress (ELCC) 2018, in Geneva, Switzerland, presented an array of exciting lung cancer trial updates. Speaking from the meeting, Marina Garassino, MD, of the Istituto Nazionale dei Tumori, Milan, Italy, discusses the Phase III ECHO-306/KEYNOTE-715 study (NCT03322566). This promising trial comprises three arms and is investigating pembrolizumab and epacadostat in non-small cell lung cancer (NSCLC). Dr Garassino discusses the design, underlying rationale and primary endpoints of the study.

Anti-angiogenic therapy has proven to be useful tool for the treatment of non-small cell lung cancer (NSCLC) in the frontline setting. Excitingly, there are now anti-angiogenic agents that can be used in the second-line setting, including ramucirumab and nintedanib, as described here by Marina Garassino, MD, of the Istituto Nazionale dei Tumori, Milan, Italy. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

The treatment of brain metastases in non-small cell lung cancer (NSCLC) is a challenge, as the majority of the drugs used to treat NSCLC exhibit low penetrance to the brain. Here, Marina Garassino, MD, of the Istituto Nazionale dei Tumori, Milan, Italy, discusses the next-generation EGFR and ALK inhibitors that can be used in cases of CNS involvement. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

Due to constraints within the NHS treatment pathway, patients with newly diagnosed multiple myeloma (MM) who are characterized as having high-risk (HR) disease face many challenges in receiving intensive treatment. Described as a novelty, the Myeloma UK (MUK) Nine b: OPTIMUM Treatment Protocol (NCT03188172) is the first UK trial to offer precision medicine for MM patients with HR disease. Here, Martin Kaiser, MD, of The Royal Marsden Hospital NHS Foundation Trust, London, UK, explains the rationale behind the MUK Nine b trial and discusses the use of genetic markers as tools to identify patients who have HR disease. With the…

Despite the controversy surrounding the design of the Tackling EArly Morbidity and Mortality in Myeloma (TEAMM) trial (ISRCTN51731976), a Phase III randomized study that assessed the benefit of antibiotic prophylaxis and its effect on healthcare-associated infections in patients with multiple myeloma (MM), follow-up results have shown that patients do benefit from the therapy. Here, Martin Kaiser, MD, of The Royal Marsden Hospital NHS Foundation Trust, London, UK, shares his thoughts on the trial, which was presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

In 2016, 250 patients with relapsed and/or refractory multiple myeloma (MM) were enrolled onto the Myeloma UK (MUK) Seven trial (NCT02406222); a randomized Phase II study that investigated whether the addition of cyclophosphamide to pomalidomide and dexamethasone improved progression-free survival (PFS). Speaking at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Martin Kaiser, MD, of The Royal Marsden Hospital NHS Foundation Trust, London, UK, discusses the systematic approach of the MUK Seven trial and shares his hopes of discovering what factors drive disease relapse.

An exciting update on the CASTOR trial was presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA. Here, Katja Weisel, MD, of University of Tübingen, Tübingen, Germany, shares the results that were presented from the long-term follow-up of the CASTOR trial (NCT02136134), a comparative Phase III study that assessed the effects of administering daratumumab combined with bortezomib and dexamethasone, compared with bortezomib and dexamethasone alone, in patients with relapsed and/or refractory multiple myeloma (MM).

Is the addition of cyclophosphamide to pomalidomide (Pom) and dexamethasone (Dex) treatment more effective at inducing a deeper and more durable remission for patients with relapsed and/or refractory multiple myeloma (MM) compared to Pom and Dex alone? Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, Katja Weisel, MD, of University of Tübingen, Tübingen, Germany, discusses the exciting results from the GMMG PERSPECTIVE trial (NCT02046915), which investigated this question.

With the recent revolution of drugs for the treatment of lung cancer, particularly non-small cell lung cancer (NSCLC), what lessons can be learned? Here, speaking at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference in Denver, CO, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, provides a brief overview of his presentation from the John G. Kuhn Keynote Lecture, ”There will be drugs”: lessons from lung cancers therapeutic oil boom.

Could being proactive, by treating lung cancer patients with next-generation drugs, help reduce the risk of acquired resistance? In this interesting interview, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, shares his thoughts on this matter, explaining the importance of understanding the biology of lung cancer and being able to predict how the cancer will behave in the future. Dr Camidge also discusses the use of osimertinib and what could be considered when deciding on the use of this drug. This interview was recorded at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

There are now four FDA approvals that have molecular-specific licenses for lung cancer, these include ALK rearrangements, EGFR mutations, BRAF V600E mutations and ROS1 rearrangements. Now, speaking at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, discusses the abnormalities that do not have FDA-approved targted drugs and raises the interesting question of who is actually benefitting from the treatment options.

How do you decide on which drug to use when treating non-small cell lung cancer (NSCLC) patients in a second-line setting? Here, speaking at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO addresses the question of how to choose between nivolumab, pembrolizumab and atezolizumab for the treatment of NSCLC.

Recently, due to the revolution of immunotherapy in the treatment of nonsmall cell lung cancer (NSCLC), more drugs are being licensed to treat patients in the second-line setting. Although overall survival in these patients has been shown to increase, the same can not be said for the rate of progression-free survival. Here, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO, discusses the importance of carefully monitoring these patients during chemotherapy. This interview was recorded at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Idasanutlin (RG7388) is an MDM2 Antagonist Induces P53-directed apoptosis at Imedex Great Debates 2018.

Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Awaiting Phase 3 for Luspatercept and ASTX727 Clinical trial accrual is an ongoing challenge in MDS at Imedex Great Debates 2018.

John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Sotatercept is an Active Ligand Trap Relieves repression of late-stage erythropoiesis at Imedex Great Debates 2018.

Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Caution Using Medicine Off-Label Limits learning from clinical studies at Imedex Great Debates 2018.

John Mascarenhas, MD, Mount Sinai School of Medicine, discusses LCL161 is a SMAC mimetic Induces Apoptosis in patients with myelofibrosis at Imedex Great Debates 2018.

Grzegorz S. Nowakowski, M.D., Mayo Clinic, explains Managing Relapse Patients Early On After Initial Therapy Clinical Trial Participation is Preferred at Imedex Great Debates 2018.

Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Few Therapeutic MDS Options for Patients Incorporating novel agents on trials in the right time at Imedex Great Debates 2018.

John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Imetelstat, Telomerase Inhibitor Myelofibrosis Intravenous drug given every 3-4 weeks at Imedex Great Debates 2018.

Grzegorz S. Nowakowski, M.D., Mayo Clinic, explains Transplantation is an Option for Aggressive Lymphoma Patients w DLBL or High-Grade Lymphoma can benefit at Imedex Great Debates 2018.

Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Novel & Combination therapies in MDS Results in SF3B1, Cytidine Deaminase Inhibitors, Decitabine at Imedex Great Debates 2018.

John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Pentraxin 2 Analogue PRM-151,Infusion agent, anti-fibrotic therapy at Imedex Great Debates 2018.

Grzegorz S. Nowakowski, M.D., Mayo Clinic, explains 25% of Patients Relapse Early in Follicular Lymphoma New targeted agents changes approach to patients at Imedex Great Debates 2018.

In the transplant setting, nurses are a vital component of patient care. Here, Michelle Kenyon, Vice Chair of the European Blood and Marrow Transplantation (EBMT) Nurses Group, a Clinical Nurse Specialist from King’s College Hospital, London, UK, highlights the utility of the EBMT Annual Meeting for Hematology Nurses, including a scientific programme and poster session specifically for the nursing field, as well as networking and collaboration opportunities. She also tells us her highlights from the meeting, covering new treatments and practices to improve the quality of patient care. This video was recorded at the EBMT 2018 Annual Meeting, held in…

An exciting new resource is available for nurses; The European Blood and Marrow Transplantation (EBMT) Textbook for Nurses. In this interview, Michelle Kenyon, Vice Chair of the EBMT Nurses Group, a Clinical Nurse Specialist from King’s College Hospital, London, UK, gives us an overview of this resource. Michelle explains how this open-access e-book is the first book specifically written for nurses with an interest in hematopoietic stem cell transplantation, and highlights the comprehensive coverage offered. This is not the end for this project; she also provides an insight into the future plans to update the e-book and expand its reach.…

On Saturday, September 16, 2017, patients, caregivers, family members and friends joined GRACE in Cleveland at the Taussig Cancer Center for a full day of discussion on Targeted Therapies in Lung Cancer. The afternoon EGFR session breakout with Dr. Nathan Pennell, Dr. H. (Jack) West, and John Cherol, EGFR patient.

Advances in immunotherapy – what lung cancer patients need to know.

Dr. West discusses blaming the victim. Thanks to Steph Kang for conception, Jack West for discussion and video, Maddy Brock for production editing and Bensound.com.

Dr. Jack West shares updates to our Lung Cancer Video Library for 2017 — Should Immunotherapy Stop in Responding Patients After a Fixed Duration of Treatment? http://cancerGRACE.org/

Dr. Jack West offers 2017 updates to the GRACE Lung Cancer Video Library discussion on the optimal follow-up for patients after resection of an early stage non-small cell lung cancer (NSCLC). IFCT0302 http://cancerGRACE.org/

Dr. Nate Pennell, Director of Lung Cancer Medical Oncology at Cleveland Clinic Taussig Cancer Center shares 2017 updates for our Lung Cancer Video Library. In this update, Dr. Pennell discusses Liquid Biopsies for EGFR T790M NSCLC.

We are pleased to have Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio share with us 2017 updates for our Lung Cancer Video Library. In this latest video, Dr. Pennell discusses Liquid Biopsies for Broad Genomic Testing in Lung Cancer. http://cancerGRACE.org/

We are pleased to have Nathan Pennell, MD, Ph.D., Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio share with us 2017 updates for our Lung Cancer Video Library. Have a question? Please visit http://cancergrace.org/forum/q-and-a-…, and scroll to the bottom of the page to post a new topic. http://cancerGRACE.org/

Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University again joined GRACE to discuss updates to the basics of lung cancer. In this (audio only, Spanish language) webcast for the Spanish lung cancer video library, Dr. Raez discusses combinations of first-line treatment, immunotherapy agents together. Please visit our forums at http://cancergrace.org/forum/q-and-a-…, and scroll to the bottom of the page to ask a question!

Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University again joined GRACE to discuss updates to the basics of lung cancer. In this (audio only, spanish language) webcast for the Spanish lung cancer video library, Dr. Raez discusses combinations of first-line treatment, immunotherapy with chemotherapy. Please visit our forums at http://cancergrace.org/forum/q-and-a-…, and scroll to the bottom of the page to ask a question!

Dr. Alice Shaw, Associate Professor of Medicine at Harvard Medical School, and Attending Physician Thoracic Cancer Program at Massachusetts General Hospital joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Shaw discusses patterns of resistance in ALK Positive Non Small Cell Lung Cancer.

Dr. Vamsidhar Velcheti, Hematology and Medical Oncology with the Cleveland Clinic Main Campus, joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Velcheti discusses MET as a Target in Advanced Non-Small Cell Lung Cancer.

Dr. Alice Shaw, Associate Professor of Medicine at Harvard Medical School, and Attending Physician Thoracic Cancer Program at Massachusetts General Hospital joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Shaw discusses the changing landscape of first-line treatment of ALK-positive advanced non-small cell lung cancer.

Dr. Alice Shaw, Associate Professor of Medicine at Harvard Medical School, and Attending Physician Thoracic Cancer Program at Massachusetts General Hospital joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Shaw discusses controlling brain metastases in patients with molecular driven advanced non-small cell lung cancer.

In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Drs. Axel Grothey, Tanios S. Bekaii-Saab, Scott Kopetz, and Neil Segal examine a series of challenging clinical cases to elucidate scenarios in which immunotherapeutic agents should be utilized in the treatment of gastrointestinal malignancies. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7292 © 2018 Imedex, LLC.

Great Debates & Updates in GI Malignancies 2018 provided expert review and guidance for the evaluation and interpretation of recent clinical data, assessment of optimal approaches for management of non-colorectal cancers, and facilitate the safe and appropriate integration of new therapies into everyday clinical practice. This activity features the conference co-chairs, Drs. Axel Grothey and David H. Ilson, discussing the key take-home messages from the second day of the conference, which focused on non-colorectal GI cancers. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7290 © 2018 Imedex, LLC.

Great Debates & Updates in GI Malignancies 2018 provided attendees with an enhanced ability to evaluate and successfully integrate optimal diagnostic, therapeutic and management strategies into everyday clinical practice. This activity features the conference co-chairs, Drs. Axel Grothey and David H. Ilson, discussing the key take-home messages from the first day of the conference, which focused on colorectal cancer. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=COLORECTAL © 2018 Imedex, LLC.

In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Dr. Neil Segal discusses best practices for the integration of immunotherapy agents into current treatment algorithms for gastrointestinal malignancies. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7292 © 2018 Imedex, LLC.

In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Dr. Scott Kopetz assesses whether or not we presently have reliable biomarkers that can be leveraged for the use of immunotherapy agents. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7292 © 2018 Imedex, LLC.

In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Dr. Tanios S. Bekaii-Saab provides an overview of recent advances in immunotherapy for the treatment of gastrointestinal malignancies. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7292 © 2018 Imedex, LLC.

In Part 3 of the ‘Optimizing Dosing Strategy for Late-Line Therapies in mCRC’ roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van Cutsem discuss the results of the REVERCE trial on therapeutic sequencing and expound upon emerging therapies for the refractory mCRC population, including HER-targeted and immunotherapies. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=CRC © 2018 Imedex, LLC.

In Part 2 of the ‘Optimizing Dosing Strategy for Late-Line Therapies in mCRC’ roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van Cutsem discuss the implications of recently published data from the phase II ReDOS trial, which evaluated dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC). Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=CRC © 2018 Imedex, LLC.

In Part 1 of the ‘Optimizing Dosing Strategy for Late-Line Therapies in mCRC’ roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van Cutsem provide an overview of current standards of care for patients with relapsed/refractory metastatic colorectal cancer. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=CRC © 2018 Imedex, LLC.

Dr. Jack West presents early data suggesting that chemotherapy may be more effective after prior immunotherapy than otherwise.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, explains how Drugs for Long-Term is a New Area for Ovarian Cancer Dont give up on path inhibitors too early because of toxicity.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Two Trials looking at Inhibitors in 1st-line Therapy Combinations, Cediranib & Olapanib, and Bevacizumab & Olapanib.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how Rucaparib is licensed as a single-agent in the US Patients using Olaparib, benefited for a long period of time.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Rucaparib, Niraparib, and Olaparib all Show Benefit. Differences between the drugs, are in their toxicities.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how Patients Should Still Test for BRCA Mutations They are in increased risk of breast cancer.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how ARIEL3 Was a Phase 3 Trial Looking at Rucaparib Significant improvement in progression-free survival.

Dr. Jack West reviews new data on patterns of acquired resistance after a response to immune checkpoint inhibitors for advanced NSCLC, along with the clinical implications of various options based on these observations.

To improve the efficacy of immunotherapy in patients with glioblastoma (GBM), the mechanisms behind the phenomenon of why bone marrow T-cell sequestration occurs in these patients needs to be understood. Here, Pakawat Chongsathidkiet, MD, of Duke University, Durham, NC, discusses the techniques being used to characterize the mechanism of action of this occurence in GBM, with the hopes of creating a strategy to reverse the effect of GBM on T-cells. This interview was recorded at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.

Glioblastoma (GBM) is a common and aggressive cancer that starts within the brain. So far, patients with GBM who undergo immunotherapy are not responding well to the treatment and poor outcomes remain. Here, speaking at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK, Pakawat Chongsathidkiet, MD, of Duke University, Durham, NC, explains a new phenomenon that may be responsible for the lack of responsiveness to immunotherapy in patients with GBM and his hopes of improving the efficacy of this treatment.

Genetic testing is not always routinely available to breast and/or ovarian cancer patients, or those at high-risk of developing these malignancies; the question is, why? And how can these challenges be tackled? Speaking at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK, Nazneen Rahman, CBE, FMedSci, of the Institute of Cancer Research, London, UK, explains the key challenges to availability. Prof. Rahman then discusses how these hurdles are being tackled and the benefits of these strategies.

Due to advancements in genetic testing, women who have breast and/or ovarian cancer, or who are at high-risk of developing these cancers, are easier to identify. Genetic testing can also lead to the identification of any relatives who have mutations in the genes responsible for the development of breast and/or ovarian cancer. In this interview, Nazneen Rahman, CBE, FMedSci, of the Institute of Cancer Research, London, UK, discusses plans to make genetic testing for breast and ovarian cancer more accessible in clinics. This interview was held at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK.

The 2018 Annual Hematology/Oncology Pharmacy Association (HOPA) Conference, held in Denver, CO, saw many thought-provoking sessions and exciting updates. Here, Kirollos Hanna, PharmD, BCOP, BCPS, of the University of Minnesota Medical Center, Minneapolis, MN, provides an overview of his presentation on updates in urothelial carcinoma. Dr Hanna also highlights the main topics of discussion during the presentation.

Here, Kirollos Hanna, PharmD, BCOP, BCPS, of the University of Minnesota Medical Center, Minneapolis, MN, gives an insight into his experience of the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO. Dr Hanna also offers an insightful perspective into the benefits of HOPA and expresses his excitement for what is to come for the oncology pharmacy community.

Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Kirollos Hanna, PharmD, BCOP, BCPS, of the University of Minnesota Medical Center, Minneapolis, MN, offers his recommendations, for colleagues in the field, on the treatment options available for muscle invasive and non-muscle invasive urothelial carcinoma. Depending on the type and severity of the disease, Dr Hannas recommendations include the use of chemotherapy, bladder preservation and immunotherapy.

Following the success of a collaborative educational training event in India run by the European Blood and Marrow Transplantation Nurses Group (EBMT NG), there are hopes for further training by the participants. Speaking from the EBMT 2018 Annual Meeting, held in Lisbon, Portugal, Meera Achrekar of Tata Memorial Centre, Mumbai, India, explains the success of the project and highlights feedback from the participants.

The future is looking bright for bladder cancer, with many clinical studies of new therapeutic options underway. Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Kirollos Hanna, PharmD, BCOP, BCPS, of the University of Minnesota Medical Center, Minneapolis, MN, provides an exciting overview of current clinical trials and discusses the challenges of treating second-line metastatic urothelial cancer. Just some of the exciting new drugs discussed include ramucirumab, cabozantinib and tremelimumab.

The European Blood and Marrow Transplantation Nurses Group (EBMT NG) started a collaborative educational training project in India, which is now to be expanded following its success. The project is introduced here by Aleksandra Babic, past President of the EBMT NG and current Chairperson of the NG Global Education Committee, from the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. Next, Meera Achrekar of Tata Memorial Centre, Mumbai, India, explains the aims of the project, highlighting the importance of this initiative and her continued excitement moving forwards. This video was recorded at the EBMT 2018 Annual Meeting, held in Lisbon, Portugal.

New and exciting developments on urothelial cancer were presented at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO. In this detailed interview, Kirollos Hanna, PharmD, BCOP, BCPS of the University of Minnesota Medical Center, Minneapolis, MN, discusses PD-L1 expression and covers the latest updates on immunotherapy options for metastatic urothelial carcinoma.

The European Blood and Marrow Transplantation Nurses Group (EBMT NG) ran a successful educational training event in India. Here, Meera Achrekar of Tata Memorial Centre, Mumbai, India, explains how she has been inspired by the EBMT NG. She passionately discusses the idea of setting up a similar group in India, highlighting the importance of a forum such as this. This video was recorded at the EBMT 2018 Annual Meeting, held in Lisbon, Portugal.

Following the success of a collaborative educational training event in India run by the European Blood and Marrow Transplantation Nurses Group (EBMT NG), the project was presented at the EBMT 2018 Annual Meeting, held in Lisbon, Portugal, by Meera Achrekar of Tata Memorial Centre, Mumbai, India. Speaking from the meeting, Meera expresses her thoughts about the conference, highlighting the utility of the nursing sessions at the meeting.

This activity has been designed to inform oncologists who manage patients with mCRC how to safely and effectively incorporate dose optimization strategies and sequencing into current clinical algorithms, and features a roundtable discussion of renowned clinical experts, Drs. Axel Grothey, Eric Van Cutsem, and Tanios S. Bekaii-Saab, on the latest advances and insights from pivotal clinical trials. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=CRC © 2018 Imedex, LLC.

Dr. Jack West summarizes the evolving data shaping our understanding of the role of immune checkpoint inhibitors for patients with EGFR- or ALK-positive advanced NSCLC, including more recent data that should change our perspective.

Graft versus host disease (GvHD) remains to be one of the leading causes of morbidity and mortality in patients who have undergone bone marrow transplant. Here, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, briefly discusses the challenges with current treatment options for GvHD and gives an update on newly approved drugs that can be used to effectively treat patients. This interview was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

It is an exciting time in the field of graft versus host disease (GvHD) research, as new drugs for the treatment of this disease in post-transplant patients have been FDA approved or received breakthrough therapy designation. Such drugs include ruxolitinib and ibrutinib, and although these drugs have shown to be effective in treating patients with GvHD, there are still challenges that pharmacists must be aware of. Here, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, explains the challenges that come with this therapy and the importance of pharmacist intervention when using ruxolitinib or ibrutinib for the treatment…

At present, the standard frontline therapy of steroids for graft versus host disease (GvHD) has shown to be ineffective for many patients. Now, speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, provides an interesting update on the use of ibrutinib or ruxolitinib for the treatment GvHD. Dr Gatwood gives an insight on current studies that are investigating the use of ruxolitinib for acute and chronic GvHD, with the hope of ruxolitinib becoming FDA approved in the future.

At the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, we asked a range of experts what they thought the key unanswered question in lung cancer is currently. They were all in agreement that there are a range of issues to address, but each speaker had their own take on the question. Ranging from disease biology to early diagnosis and policy, see what the experts thought.

A record number of delegates attended the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland. Although exciting advancements in research and practice were presented, but the attendees emphasize that this is not the only reason that they attend the BTOG conference every year. For an expert insight into the meeting, hear from the presenters themselves. See you at BTOG 2019!

Dr. Jack West reviews the preliminary positive result form the IMpower131 trial of chemo +/- atezolizumab immunotherapy and considers what the clinical significance of these findings should be for patients with advanced squamous NSCLC.

Maxine Sun, MD Dana-Farber Cancer Institute, discusses how Statistical Analysis Plans are Useful for Clinician Scientists They can go over statistical methods that they believe will be pertinent at Kidney Cancer Association 2017 in Miami.

Walter M. Stadler, MD University of Chicago, discusses Genomic and Expression Profling Soon to be part of treatment decision making at Kidney Cancer Association 2017 in Miami.

Maxine Sun, MD Dana-Farber Cancer Institute, discusses Planning and Identification of the Statistical Methodologies Consult biostatistician for opinions on the feasibility of techniques at Kidney Cancer Association 2017 in Miami.

Brian M. Shuch, MD Yale School of Medicine, discusses how S1500’s Completion May Alter Standard of Care for PRCC Compares 3 pool MET inhibitors to Sutent as a comparator arm at Kidney Cancer Association 2017 in Miami.

Walter M. Stadler, MD University of Chicago, discusses how they May Select Patients for VEGF or PD-1 Targeted Further investigation in other immunotherapies at Kidney Cancer Association 2017 in Miami.

Maxine Sun, MD Dana-Farber Cancer Institute, discusses The Importance of Statistical Analysis Plans Minimize errors, reduce amount of surprises, & diminish data mining at Kidney Cancer Association 2017 in Miami.

Robert Uzzo, MD Fox Chase Cancer Center, discusses the Role of Government in Health Care Political climate raises questions on health care as a right at Kidney Cancer Association 2017 in Miami.

Walter M. Stadler, MD University of Chicago, discusses Biomarker Data From Phase II Trial Preliminary expression profiling at Kidney Cancer Association 2017 in Miami.

Brian M. Shuch, MD Yale School of Medicine, discusses the SWOG S1500 – Randomized Phase II Trial Efficacy assessment of multiple MET kinase inhibitors in metastatic PRCC at Kidney Cancer Association 2017 in Miami.

Tian Zhang, MD Duke University Medical Center, explains the Challenges of VEGF & Immunotherapy Combinations Resistance patterns in patients disease progression at Kidney Cancer Association 2017 in Miami.

Robert Uzzo, MD Fox Chase Center, explains how Value is a Function of Outcomes and Cost Optimal care is not always related to more or less expensive care at Kidney Cancer Association 2017 in Miami.

Walter M. Stadler, MD University of Chicago, discusses Biomarker Data From Phase II Randomized Trial Study of Atezolizumab With or Without Bevacizumab v Sunitinib at Kidney Cancer Association 2017 in Miami.

Brian M. Shuch, MD Yale School of Medicine, discusses the Difference Between Type 1 & 2 PRCC Although look similar on light microscopy, they have different biology at Kidney Cancer Association 2017 in Miami.

Maxine Sun, MD Dana-Farber Cancer Institute, discusses The Use of Secondary Data Analysis Opportunity to produce high-impact research at Kidney Cancer Association 2017 in Miami.

Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers if there is Any association between PDL-1 expression by the tumor?

Andrew Chi, MD, PhD at NYU Langone Medical Center Explains how Gliomas in Mid-Line Locations are Distinct in Both Genetic Makeup and Behavior. Clinical Trial: ONC201 in Adults With Recurrent H3 K27M High-grade Glioma.

Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center answers how Data will not affect clinicians at the moment. Still a Phase 1 study